Rainforest Acquisition

TriSalus Life Sciences is a commercial-stage medical technology and clinical-stage biopharmaceutical company focused on improving outcomes for patients with liver and pancreatic tumors. The company utilizes its proprietary Pressure-Enabled Drug Delivery (PEDD) technology, which includes the FDA-cleared TriNav Infusion System, to overcome the high pressure within solid tumors that often limits the effectiveness of systemic therapies. Their lead therapeutic candidate, SD-101, is a class C Toll-like receptor 9 (TLR9) agonist designed to modulate the immunosuppressive tumor microenvironment. TriSalus is currently conducting multiple Phase 1/2 clinical trials evaluating SD-101 delivered via PEDD in combination with standard-of-care treatments. By integrating specialized hardware with targeted therapeutics, the company aims to enhance the efficacy of treatments in orphan indications with high unmet needs.